°¢¶û´Äº£Ä¬²¡£¨AD£©ÊÇÊÀ½ç·¶Î§ÄÚ×î³£¼ûµÄ³Õ´ôÖ¢¡£ÔÚ°¢¶û´Äº£Ä¬²¡ÒÅ´«·çÏÕÒòËØÖУ¬ApoE£¨ÔØÖ¬ÂѰ×E£©»ùÒòÊÇ×îÒªº¦ºÍ×îÆÕ±éµÄ£¬Ó°ÏìÁËÒ»°ëÒÔÉϵÄAD²¡Àý¡£APOE»ùÒòµÄε4µÈλ»ùÒòÏÔÖøÔö¼ÓAD·çÏÕ£¬¶øε2µÈλ»ùÒòÏà¶ÔÓÚ³£¼ûµÄε3µÈλ»ùÒò¾ßÓб£»¤×÷Óá£ÕâЩ»ùÒòµÈλ»ùÒò±àÂëÈýÖÖÔØÖ¬ÂѰ×ÑÇÐÍ¡£ApoEµÄÖ÷ÒªÉúÀí¹¦Ð§Êǽ鵼ÄÔºÍÍâÖÜ×éÖ¯ÖеÄÖ¬ÖÊתÔË£»ÔÚÖ²¡ÐÔÉÏ£¬ApoE4Çý¶¯µí·ÛÑùÂѰ׸üÔçºÍ¸ü¸»ºñµÄ·¢Éú¡£
ͼ1 ApoEµÄ½á¹¹Ä£ÐÍ
ApoEÊÇÒ»ÖÖ299¸ö°±»ùËáµÄÌÇÂѰף¬·Ö×ÓÁ¿Îª34 kDa¡£N¶Ë½á¹¹Óò£¨²Ð»ù1-167£©°üÂÞÊÜÌå½áºÏÇø£¬¶øC¶Ë½á¹¹Óò£¨²Ð»ù206-299£©°üÂÞÖ¬ÖʽáºÏÇø¡£ÈýÖÖÖ÷ÒªµÄÔØÖ¬ÂѰ×Òì¹¹ÌåÐγÉÊÇÓÉÓÚ112ºÍ158°±»ùËá²îÒ죺ApoE2 (C112 / C158)£»ApoE3 (C112/ R158)£»ApoE4£¨R112 / R158£©¡£
ͼ2 Õë¶ÔApoE½øÐа¢¶û´Äº£Ä¬²¡ÖÎÁƵĶàÖÖ¼ÆÄ±
Õë¶ÔApoE½øÐа¢¶û´Äº£Ä¬²¡ÖÎÁÆÓжàÖÖ¼ÆÄ±£¬Ê×ÏȰ¢¶û´Äº£Ä¬²¡Äܹ»Í¨¹ýµ÷ÖÎÖÖÖÖϸ°ûÀàÐ͵ÄApoE±í´ï½øÐÐÖÎÁÆ¡£LXR/RXRsÊÇApoE±í´ïµÄÉÏÓε÷¿ØÒò×Ó£¬Êǵ÷ÖÎApoEˮƽµÄºÏÊʰе㣬ͨ¹ýLXR/RXR¼¤¶¯¼Á¿ÉÒÔÔö¼ÓApoE±í´ïˮƽºÍÖ¬»¯¡£
ÁíÒ»ÖÖÕë¶ÔÔØÖ¬ÂѰ×EµÄÖÎÁƼÆÄ±ÊÇʹÓõ÷ÖÎÔØÖ¬ÂѰ×E¹¦Ð§µÄС·Ö×Ó¡£°üÂÞÉè¼ÆÄ£ÄâApoEÔÚLDLºÍHDLÉϵĽáºÏλµãµÄëÄ£¬ÕâÒѱ»Ö¤Ã÷¿ÉÒÔÔö¼ÓApoEµÄÖ¬»¯ºÍÅÅй¡£´ËÍ⣬ģÄâëÄ¿ÉÒÔÔöÇ¿ApoEÊÜÌåµÄ¹¦Ð§£¬¸ÄÉÆµ¨¹Ì´¼µÄתÔË¡£Í¬Ñù£¬µ÷ÖÎApoEµÄÖ¬»¯Ò²³ÉΪһ¸öÄ¿±ê£¬Ä£ÄâëÄ¿ÉÒÔÔö¼ÓABCA1µÄ»îÐÔ£¬´Ó¶øÔö¼ÓApoE4µÄÖ¬»¯²¢¸ÄÉÆÈÏÖª¹¦Ð§¡£ÁíÒ»¸öÓÐÏ£ÍûµÄÖÎÁÆÍ¾¾¶ÊÇͨ¹ý»ùÒò±à¼¶ÔÔØÖ¬ÂѰ×E½øÐнṹÐÞÊΡ£CRISPR/Cas9ϵͳÓпÉÄÜÖ±½Ó½«ApoE4ת»¯ÎªApoE3»òApoE2¡£×îºó£¬°ÐÏòÍâÖÜÔØÖ¬ÂѰ×E¿ÉÄÜÊÇADÖÎÁƵÄÁíÒ»ÖÖ;¾¶¡£ÀýÈ磬ͨ¹ýÔÚApoE4Я´øÕßÖÐ×¢ÈëApoE3Ѫ½¬½øÐÐѪ½¬½»»»£¬Ä¿Ç°ÕýÔÚÁÙ´²ÊÔÑéÖС£
Ëæ×ŶÔÔØÖ¬ÂѰ×EµÄ½á¹¹¹¦Ð§ÒÔ¼°ÔØÖ¬ÂѰ×EÓëÉñ¾²¡ÀíÖ®¼äµÄ»úÖÆ¹ØÏµµÄ½øÒ»²½Ñо¿£¬Äܹ»Í¨¹ýµ÷ÖÎÔØÖ¬ÂѰ×EµÄˮƽ¡¢½á¹¹¡¢Ö¬»¯¡¢¹Ñ¾Û»¯ºÍÏà¹Ø½á¹ûÀ´¸Ä±ä²¡Àí½øÕ¹¡£ÁíÍâÀûÓöà×éѧ·ÖÎö¡¢Ï¸°ûÀàÐÍÌØÒìÐÔ¹¦Ð§ºÍеÄApoE±äÒìÀ´Ì½Ë÷ϵͳ±ä»¯µÄ½øÒ»²½Ñо¿£¬¿ÉÄÜ»áÔÚδÀ´µÄ°¢¶û´Äº£Ä¬²¡ÖÎÁÆÉú³¤Öз¢ÉúÒªº¦µÄ×÷Óá£
²Î¿¼ÎÄÏ×
Ana-Caroline Raulin, et al. ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies. Mol Neurodegener. 2022 Nov 8; 17(1): 72. doi: 10.1186/s13024-022-00574-4.